Agilent to Pay $950M for Biocare, Targeting 12-Month EPS Accretion
Agilent Technologies will acquire Biocare Medical for $950 million in cash to gain control of its IHC, ISH and FISH pathology solutions and 300 specialized antibodies. The deal is expected to close by Q4 FY2026 and become EPS accretive within 12 months post-close, bolstering Agilent’s Life Sciences and Diagnostics segment.
1. Acquisition Overview
Agilent Technologies has agreed to acquire Biocare Medical in a $950 million cash transaction, gaining ownership of Biocare’s immunohistochemistry (IHC), in situ hybridisation (ISH) and fluorescence in situ hybridisation (FISH) products designed for oncology and clinical pathology.
2. Product Portfolio Expansion
Biocare’s catalogue includes more than 300 specialised antibodies, which Agilent will integrate to enhance its in vitro diagnostic (IVD) development and commercialisation capabilities, accelerating innovation in both research and clinical settings.
3. Financial and Segment Impact
The transaction is slated to close by the fourth quarter of Agilent’s 2026 fiscal year and is projected to be accretive to earnings per share approximately 12 months after closing; Biocare will join the Life Sciences and Diagnostics Markets Group, which generated $679 million in Q1 revenue, up 5% year-over-year.
4. Strategic Rationale
Combining Agilent’s global operations with Biocare’s US commercial presence aims to broaden the customer base and strengthen the company’s pathology portfolio, aligning with Agilent’s strategy of customer-centric innovation and disciplined capital allocation.